Uncategorized Archives - Page 5 of 6 - HealthCare Royalty

May 24, 2018

Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®

May 14, 2018

U.S. Food and Drug Administration Accepts and Acknowledges Coherus Biosciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) For Review

May 10, 2018

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

May 4, 2018

U.S. FDA Approves Portola Pharmaceuticals’ Andexxa^®, First and Only Antidote for the Reversal of Factor Xa Inhibitors

April 19, 2018

HealthCare Royalty Partners Appoints Four New Partners

January 26, 2018

GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over

January 19, 2018

Albireo to Receive More than $55 Million ⁽¹⁾ in Nondilutive Cash Payments

January 8, 2018

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

January 3, 2018

Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan

November 17, 2017

Acorda Announces Royalty Monetization Transactions for $53 Million